João Pedro Ferreira1,2, Francisco Vasques-Nóvoa2, Diana Ferrão2, Francisca Saraiva2, Inês Falcão-Pires2, João Sérgio Neves2,3, Abhinav Sharma4, Patrick Rossignol1, Faiez Zannad1, Adelino Leite-Moreira2. 1. INSERM, Centre d'Investigations Cliniques - Plurithématique 14-33, Université de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. 2. Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal. 3. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal. 4. DREAM-CV Lab, Division of Cardiology, McGill University Health Centre, Montreal, Canada.
Abstract
OBJECTIVE: Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis. Fenofibrate may reduce HF events through multiple mechanisms. We sought to study the effect of fenofibrate (vs. placebo) in HF outcomes among patients with T2D receiving simvastatin enrolled in the Action to Control Cardiovascular Risk in Diabetes lipid trial (ACCORD Lipid). RESEARCH DESIGN AND METHODS: We used Cox regression analysis with background glucose-lowering strategy as the stratification variable. The median follow-up was 4.7 years. RESULTS: A total of 5,518 patients were included. Median age was 62 years, and 31% were women. Prior HF history was present in 5% of the patients. The composite outcome of HF hospitalization or cardiovascular death occurred in 190 (6.9%) patients in the fenofibrate group vs. 228 (8.3%) in the placebo group: HR 0.82, 95% CI 0.68-1.00 (P = 0.048). The beneficial effect of fenofibrate to reduce HF hospitalizations or cardiovascular death was present among patients receiving standard glucose-lowering strategy, HR 0.64, 95% CI 0.48-0.85, and not among patients receiving intensive glucose-lowering strategy, HR 1.02, 95% CI 0.79-1.33 (Pinteraction = 0.017). A similar pattern was observed for HF hospitalizations alone. The effect of fenofibrate on blood lipids was not influenced by background glucose-lowering therapy in a clinically important manner. Fenofibrate caused more transient worsening estimated glomerular filtration rate (eGFR) events but slowed long-term eGFR decline. CONCLUSIONS: In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy.
OBJECTIVE: Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis. Fenofibrate may reduce HF events through multiple mechanisms. We sought to study the effect of fenofibrate (vs. placebo) in HF outcomes among patients with T2D receiving simvastatin enrolled in the Action to Control Cardiovascular Risk in Diabetes lipid trial (ACCORD Lipid). RESEARCH DESIGN AND METHODS: We used Cox regression analysis with background glucose-lowering strategy as the stratification variable. The median follow-up was 4.7 years. RESULTS: A total of 5,518 patients were included. Median age was 62 years, and 31% were women. Prior HF history was present in 5% of the patients. The composite outcome of HF hospitalization or cardiovascular death occurred in 190 (6.9%) patients in the fenofibrate group vs. 228 (8.3%) in the placebo group: HR 0.82, 95% CI 0.68-1.00 (P = 0.048). The beneficial effect of fenofibrate to reduce HF hospitalizations or cardiovascular death was present among patients receiving standard glucose-lowering strategy, HR 0.64, 95% CI 0.48-0.85, and not among patients receiving intensive glucose-lowering strategy, HR 1.02, 95% CI 0.79-1.33 (Pinteraction = 0.017). A similar pattern was observed for HF hospitalizations alone. The effect of fenofibrate on blood lipids was not influenced by background glucose-lowering therapy in a clinically important manner. Fenofibrate caused more transient worsening estimated glomerular filtration rate (eGFR) events but slowed long-term eGFR decline. CONCLUSIONS: In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy.
Authors: Alessandra Dei Cas; Sadiya S Khan; Javed Butler; Robert J Mentz; Robert O Bonow; Angelo Avogaro; Diethelm Tschoepe; Wolfram Doehner; Stephen J Greene; Michele Senni; Mihai Gheorghiade; Gregg C Fonarow Journal: JACC Heart Fail Date: 2015-02 Impact factor: 12.035
Authors: João Pedro Ferreira; Job Verdonschot; Timothy Collier; Ping Wang; Anne Pizard; Christian Bär; Jens Björkman; Alessandro Boccanelli; Javed Butler; Andrew Clark; John G Cleland; Christian Delles; Javier Diez; Nicolas Girerd; Arantxa González; Mark Hazebroek; Anne-Cécile Huby; Wouter Jukema; Roberto Latini; Joost Leenders; Daniel Levy; Alexandre Mebazaa; Harald Mischak; Florence Pinet; Patrick Rossignol; Naveed Sattar; Peter Sever; Jan A Staessen; Thomas Thum; Nicolas Vodovar; Zhen-Yu Zhang; Stephane Heymans; Faiez Zannad Journal: Circ Heart Fail Date: 2019-05 Impact factor: 8.790
Authors: T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech Journal: Diabetologia Date: 2010-11-04 Impact factor: 10.122
Authors: H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: John B Buse; J Thomas Bigger; Robert P Byington; Lawton S Cooper; William C Cushman; William T Friedewald; Saul Genuth; Hertzel C Gerstein; Henry N Ginsberg; David C Goff; Richard H Grimm; Karen L Margolis; Jeffrey L Probstfield; Denise G Simons-Morton; Mark D Sullivan Journal: Am J Cardiol Date: 2007-04-16 Impact factor: 2.778
Authors: Li Shen; Rasmus Rørth; Deborah Cosmi; Søren Lund Kristensen; Mark C Petrie; Franco Cosmi; Roberto Latini; Lars Køber; Inder S Anand; Peter E Carson; Christopher B Granger; Michel Komajda; Robert S McKelvie; Scott D Solomon; Lidia Staszewsky; Karl Swedberg; Thao Huynh; Michael R Zile; Pardeep S Jhund; John J V McMurray Journal: Eur J Heart Fail Date: 2019-07-04 Impact factor: 15.534
Authors: Job A J Verdonschot; João Pedro Ferreira; Faiez Zannad; Stephane R B Heymans; Pierpaolo Pellicori; Hans-Peter Brunner-La Rocca; Andrew L Clark; Franco Cosmi; Joe Cuthbert; Nicolas Girerd; Beatrice Mariottoni; Johannes Petutschnigg; Patrick Rossignol; John G F Cleland Journal: Cardiovasc Diabetol Date: 2021-08-09 Impact factor: 9.951